CTXR
HEALTHCARECitius Pharmaceuticals Inc
$0.67-0.02 (-3.00%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CTXR Today?
No stock-specific AI insight has been generated for CTXR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.57$2.48
$0.67
Fundamentals
Market Cap$18M
P/E Ratio—
EPS$-2.46
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume693K
Avg Volume (10D)—
Shares Outstanding27.5M
CTXR News
21 articles- Citius Pharmaceuticals Amends Promissory Note to Enhance FlexibilityTipRanks·May 8, 2026
- Citius Oncology Ships First International Order of LYMPHIR™ to EuropeYahoo Finance·Apr 29, 2026
- Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq RulesYahoo Finance·Apr 24, 2026
- Citius Pharmaceuticals Secures $5M Through Equity OfferingAdvfn·Apr 24, 2026
- Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq RulesYahoo Finance·Apr 24, 2026
- We Might See A Profit From Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) SoonYahoo Finance·Apr 21, 2026
- Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical DevelopmentYahoo Finance·Mar 31, 2026
- Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma ExpertsYahoo Finance·Mar 24, 2026
- Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic CancersYahoo Finance·Mar 10, 2026
- Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIRYahoo Finance·Mar 6, 2026
- Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development ProgramYahoo Finance·Feb 24, 2026
- Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™Yahoo Finance·Feb 13, 2026
- Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™Yahoo Finance·Feb 13, 2026
- Citius Oncology and Uniphar sign European distribution deal for LymphirPharmaceutical-technology·Feb 12, 2026
- Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with UnipharYahoo Finance·Feb 11, 2026
- Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Dec 23, 2025
- Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Dec 23, 2025
- Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq RulesYahoo Finance·Dec 10, 2025
- Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq RulesYahoo Finance·Dec 9, 2025
- Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-KimYahoo Finance·Dec 4, 2025
- Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)Yahoo Finance·Dec 1, 2025
All 21 articles loaded
Price Data
Open$0.69
Previous Close$0.69
Day High$0.71
Day Low$0.67
52 Week High$2.48
52 Week Low$0.57
52-Week Range
$0.57$2.48
$0.67
Fundamentals
Market Cap$18M
P/E Ratio—
EPS$-2.46
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume693K
Avg Volume (10D)—
Shares Outstanding27.5M
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products. The company is headquartered in Cranford, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—